Scroll Top
Overview
Corporate Summary

Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate GT-02287 for the treatment of Parkinson’s disease and other neurodegenerative diseases is currently being evaluated in a Phase 1 clinical trial. With its Magellan drug discovery platform, Gain is transforming drug discovery by integrating Al, physics-based methods and supercomputing power to discover novel allosteric binding sites and potential first-in-class drug candidates from on-demand libraries with 5 trillion compounds in less than 3 months.

PRESENTATIONS
December 2024

Corporate Presentation

Q4 2024

Investor Factsheet

Press releases
Events
Stock information
Stock Data